Patient #. sex; age, years | Cancer, Stage | Chemotherapy regimen; anthracycline, cumulative dose, mg/m2 | Cardiac history | Before the start of anthracycline chemotherapy | LVEF, %, by time since anthracycline therapy | |||||
---|---|---|---|---|---|---|---|---|---|---|
ACEi | Beta Blocker | Aldosterone Antagonist | Pre | During | Post | 6 months post | ||||
Without dexrazoxane (controls) | ||||||||||
 1. M; 87 | PTCL, IV | CHOP Doxorubicin, 300 | NICM | Yes | Yes | Yes | 45 | – | 10 | – |
 2. M; 66 | DLBCL, IV | R-EPOCH Doxorubicin, 120 | Ischemic Cardiomyopathy | Yes | Yes | No | 40 | 15 | – | – |
 3. M; 65 | AML, M4 | Cytarabine + Daunorubicin Daunorubicin, 540 | Chemotherapy- related cardiomyopathy | Yes | No | Yes | 55 | 45 | 30 | 30 |
With dexrazoxane | ||||||||||
 4. F; 67a | HL, IIIB | ABVD Doxorubicin, 300 | NICM | Yes | Yes | No | 35 | 35 | 35 | 25 |
 5. F; 75 | DLBCL, IIISE | CHOP Doxorubicin, 300 | NICM | Yes | Yes | Yes | 35 | 35 | 35 | 30 |
 6. F 70 | Ovarian, IV | Doxorubicin, 280 | NICM | No | Yes | No | 45 | 40 | 40 | 40 |
 7. M; 73 | NHL, IV | ABVD Doxorubicin, 300 | Ischemic cardiomyopathy | Yes | Yes | Yes | 40 | 40 | 40 | 40 |
 8. F; 68 | Breast, IV | Doxorubicin Doxorubicin, 300 | NICM | Yes | Yes | No | 40 | 40 | 40 | 35 |